vicagrel

Phase 3Small molecule

JJiangsu vcare pharmaceutical technology co., LTD

vicagrel is one of 32 small molecule programs targeting Acute Coronary Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Coronary SyndromeActive, not recruiting

Acute Coronary SyndromePhase 3

Active, not recruiting

Competition

Competitive Landscape

183 competitors in Acute Coronary Syndrome

#DrugCompanyPhaseTrials

Repatha

Amgen

Phase 3

5 2

Lovenox

Sanofi

Phase 3

4 3

Eliquis

Bristol-Myers Squibb

Phase 3

3 4

Avapro

Sanofi

Phase 3

1 5

Farxiga

AstraZeneca

Phase 3

1 6

Fluzone

Nesina

1 8

Acetylsalicylic Acid

Bayer

Phase 3

5 9

Ranexa

MMenarini International Operations Luxembourg SA

Phase 3

1 10

Chantix

PPrism Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Acute Coronary Syndrome

NCT06577519

Clinical

Trials by Indication[1]

Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 3·NCT06577519·1,000 enrolled

ESS1 trial

Assessment of the Effect of Omeprazole on Vicagrel in Healthy Subjects

Unknown status·JJiangsu vcare pharmaceutical technology co., LTD·Phase 1·NCT05651074·20 enrolled

Adult Subject1 trial

Pharmacokinetics and Pharmacodynamics of Vicagrel in Healthy Adult Subjects of Different CYP2C19

Completed·JJiangsu vcare pharmaceutical technology co., LTD·Phase 1·NCT03942458·50 enrolled

2 more indications

Antiplatelet Therapy1 trial

The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel

Completed·JJiangsu vcare pharmaceutical technology co., LTD·Phase 2·NCT03599284·279 enrolled

Unspecified1 trial

The Mass Balance and Biotransformation of [14C] Vicagrel in Healthy Man

Completed·JJiangsu vcare pharmaceutical technology co., LTD·Phase 1·NCT04143750·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for vicagrel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vicagrel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vicagrel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu vcare pharmaceutical technology co., LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu vcare pharmaceutical technology co., LTD

vicagrel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Clopidogrel2 trials

Clinical Trial1 trial

Acute Coronary Syndrome1 trial

ESS1 trial

Adult Subject1 trial

Antiplatelet Therapy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News